- Page 1/4
Signal
Opinion
Expert
TOP PICK
TOP PICK
Stockchase Research Editor: Michael O'Reilly Fresh buying by a key investment fund and a re-iterated buy with a $60 price target by another is bringing INTC back into favour. With a PE of only 9x, compared to the sector average of 71x, it is good value now. Another catalyst is the announcement that Dish Network will use their products for their 5G roll out. It pays a good dividend, backed by a 25% payout ratio. We would buy this with a $40 stop-loss, looking to achieve $58 – 24% upside. Yield 2.91% (Analysts’ price target is $57.83)
TOP PICK
TOP PICK
November 24, 2020
Stockchase Research Editor: Michael O'Reilly MATW provides end of life and mortuary services. Recent earnings resulted in a record cash generating flow for the company, which allowed a $100 million reduction in debt. It trades at 9x earnings as earnings are expected to grow over 5% next year. It pays a good dividend that has increased for 22 consecutive years. We would buy this with a stop-loss at $22.00, looking to achieve $45 – 54% upside. Yield 3.04% (Analysts’ price target is $45.00)
Show full opinionHide full opinion
Stockchase Research Editor: Michael O'Reilly MATW provides end of life and mortuary services. Recent earnings resulted in a record cash generating flow for the company, which allowed a $100 million reduction in debt. It trades at 9x earnings as earnings are expected to grow over 5% next year. It pays a good dividend that has increased for 22 consecutive years. We would buy this with a stop-loss at $22.00, looking to achieve $45 – 54% upside. Yield 3.04% (Analysts’ price target is $45.00)
TOP PICK
TOP PICK
November 24, 2020
Stockchase Research Editor: Michael O'Reilly REGN’s COV2 antibody treatment used by the US President during his treatment has been granted Emergency Use Authorization by the FDA. Even though vaccine alternatives are coming, this will provide treatment options for those infected and will help reduce hospitalizations. We would buy this with a $425 stop-loss looking to achieve $630 – 21% upside. Yield 0% (Analysts’ price target is $628.52)
Show full opinionHide full opinionStockchase Research Editor: Michael O'Reilly REGN’s COV2 antibody treatment used by the US President during his treatment has been granted Emergency Use Authorization by the FDA. Even though vaccine alternatives are coming, this will provide treatment options for those infected and will help reduce hospitalizations. We would buy this with a $425 stop-loss looking to achieve $630 – 21% upside. Yield 0% (Analysts’ price target is $628.52)
PAST TOP PICK
PAST TOP PICK
November 24, 2020
(A Top Pick Sep 08/20, Up 27.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in CNR has achieved its $9.50 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $7.50 – just above our initial buy recommendation.
Show full opinionHide full opinion(A Top Pick Sep 08/20, Up 27.8%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in CNR has achieved its $9.50 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $7.50 – just above our initial buy recommendation.
PAST TOP PICK
PAST TOP PICK
November 24, 2020
(A Top Pick Aug 11/20, Up 34%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in MU has achieved its $64 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $50 – just above our initial buy recommendation.
Show full opinionHide full opinion(A Top Pick Aug 11/20, Up 34%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in MU has achieved its $64 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $50 – just above our initial buy recommendation.
PAST TOP PICK
PAST TOP PICK
November 24, 2020
(A Top Pick Oct 29/20, Up 31.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in NCR has achieved its $27 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $20.50 – near to our initial buy recommendation.
Show full opinionHide full opinion(A Top Pick Oct 29/20, Up 31.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in NCR has achieved its $27 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $20.50 – near to our initial buy recommendation.
PAST TOP PICK
PAST TOP PICK
November 24, 2020
(A Top Pick Aug 13/20, Up 29.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in SPG has achieved its $86 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $59.00 – near to our initial buy recommendation.
Show full opinionHide full opinion(A Top Pick Aug 13/20, Up 29.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK in SPG has achieved its $86 objective. To be disciplined, we are recommending covering 50% of the position and trailing up the stop to $59.00 – near to our initial buy recommendation.
Stockchase Research Editor: Michael O'Reilly Fresh buying by a key investment fund and a re-iterated buy with a $60 price target by another is bringing INTC back into favour. With a PE of only 9x, compared to the sector average of 71x, it is good value now. Another catalyst is the announcement that Dish Network will use their products for their 5G roll out. It pays a good dividend, backed by a 25% payout ratio. We would buy this with a $40 stop-loss, looking to achieve $58 – 24% upside. Yield 2.91% (Analysts’ price target is $57.83)